Hidradenitis suppurativa: A review of cause and treatment

Current Opinion in Infectious Diseases

Volumn 24, Issue 2, 2011, Pages 118-123

  Yazdanyar, Shiva ^a   Jemec, Gregor Be ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cause; hidradenitis suppurativa; immunology; treatment

Indexed keywords

CLINDAMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYPROTERONE ACETATE; DAPSONE; ESTROGEN; ETHINYLESTRADIOL; FUSIDIC ACID; RESORCINOL; RIFAMPICIN; TETRACYCLINE;

ADJUVANT THERAPY; ANTIMICROBIAL THERAPY; APOCRINE GLAND; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL INFECTION; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; ESCHERICHIA COLI; HAIR FOLLICLE; HYPERKERATOSIS; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; LOW LEVEL LASER THERAPY; OBESITY; RISK FACTOR; SKIN; SMOKING; STAPHYLOCOCCUS; SUPPURATIVE HIDRADENITIS;

ANTI-BACTERIAL AGENTS; AXILLA; CHRONIC DISEASE; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOMODULATION; MALE; OBESITY; RISK FACTORS; SMOKING;

EID: 79952189445     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283428d07     Document Type: Article

References (56)

1. Jemec GB, Revuz J, Leyden J. Hidradenitis suppurativa, 1st ed. New York, NY, USA: Springer; 2006.
2. Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17:455-456.
3. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23:985-998.
4. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35:191-194.
5. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59:596-601.
6. Der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144:809-813. (Pubitemid 32374785)
7. Esmann S, Dufour ND, Jemec GB. Questionnaire based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions. Br J Dermatol 2010; 163:102-106.
8. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010; 62:706-708.
9. Solarski ST. Living with hidradenitis suppurativa. Dermatol Nurs 2004; 16:447-449.
10. Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56:621-623. (Pubitemid 46400178)
11. Berna-Serna JD, Berna-Mestre JD. Follicular occlusion due to hyperkeratosis: a new hypothesis on the pathogenesis of mammillary fistula. Med Hypotheses 2010; 75:553-554.
12. Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122:763-769. (Pubitemid 20182193)
13. Brook I, Frazier EH. Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J Med Microbiol 1999; 48:103-105. (Pubitemid 29131423)
14. Jemec GB, Faber M, Gutschik E, Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology 1996; 193:203-206. (Pubitemid 26361521)
15. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140:90-95. (Pubitemid 29074537)
16. Wortsman X, Revuz J, Jemec GB. Lymph nodes in hidradenitis suppurativa. Dermatology 2009; 219:22-24.
17. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89:595-600.
18. Ahmed AA, Nordlind K, Schultzberg M, Liden S. Immunohistochemical localization of IL-1 alpha-, IL-1 beta-, IL-6-and TNF-alpha-like immunoreactivities in human apocrine glands. Arch Dermatol Res 1995; 287:764-766.
19. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56:624-628. (Pubitemid 46400174)
20. Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral cyclosporin. Clin Exp Dermatol 2006; 31:154-155.
21. Hunger RE, Surovy AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158:691-697. (Pubitemid 351415729)
22. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156:51-56. (Pubitemid 44924144)
23. Yazdanyar S, Miller IM, Jemec GB. Hidradenitis suppurativa and Crohn's disease: two cases that support an association. Acta Dermatovenerol Alp Panonica Adriat 2010; 19:23-25.
24. Quaglietta L, te Velde A, Staiano A, et al. Functional consequences of NOD2/ CARD15 mutations in Crohn's disease. J Pediatr Gastroenterol Nutr 2007; 44:529-539. (Pubitemid 46684353)
25. Torok HP, Glas J, Lohse P, Folwaczny C. Alterations of the CARD15/NOD2 gene and the impact on management and treatment of Crohn's disease patients. Dig Dis 2003; 21:339-345. (Pubitemid 38209791)
26. Zhang H, Massey D, Tremelling M, Parkes M. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull 2008; 87:17-30.
27. Yazdanyar S, Weischer M, Nordestgaard BG. Genotyping for NOD2 genetic variants and Crohn's disease: a metaanalysis. Clin Chem 2009; 55:1950-1957.
28. Nassar D, Hugot JP, Wolkenstein P, Revuz J. Lack of association between CARD15 gene polymorphisms and hidradenitis suppurativa: a pilot study. Dermatology 2007; 215:359. (Pubitemid 47519268)
29. Konig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198:261-264. (Pubitemid 29281414)
30. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161:831-839.
31. Lapins J, Asman B, Gustafsson A, et al. Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 2001; 81:96-99. (Pubitemid 32662147)
32. Parks RW, Parks TG. Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl 1997; 79:83-89. (Pubitemid 27136113)
33. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26:638-643. (Pubitemid 30470626)
34. Edlich RF, Silloway KA, Rodeheaver GT, Cooper PH. Epidemiology, pathology, and treatment of axillary hidradenitis suppurativa. J Emerg Med 1986; 4:369-378. (Pubitemid 17219194)
35. Mortimer PS, Lunniss PJ. Hidradenitis suppurativa. J R Soc Med 2000; 93:420-422. (Pubitemid 30649438)
36. Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ 1989; 298:28-29. (Pubitemid 19022887)
37. Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988; 119:345-350.
38. Mortimer PS, Dawber RP, Gales MA, Moore RA. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) 1986; 292:245-248. (Pubitemid 16161990)
39. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22:325-328. (Pubitemid 13107515)
40. Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010; 35:36-40.
41. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39:971-974. (Pubitemid 28547731)
42. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219:148-154.
43. Van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219:143-147.
44. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40:73-76. (Pubitemid 29051027)
45. Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology 2009; 218:134-135.
46. Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Br J Dermatol 2010 [Epub ahead of print].
47. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62:205-217.
48. Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63:475-480.
49. Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998; 13:164-168. (Pubitemid 28444875)
50. Buimer MG, Ankersmit MF, Wobbes T, Klinkenbijl JH. Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study. Dermatol Surg 2008; 34:224-227.
51. Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol 1994; 131:551-556. (Pubitemid 24315426)
52. Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 2009; 35:1188-1198.
53. Frohlich D, Baaske D, Glatzel M. Radiotherapy of hidradenitis suppurativa: still valid today? Strahlenther Onkol 2000; 176:286-289.
54. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135:721-725. (Pubitemid 26375888)
55. McKeage K, Deeks ED. Doxycycline 40mg capsules (30mg immediaterelease/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol 2010; 11:217-222.
56. Dufour DN, Bryld LE, Jemec GB. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology 2010; 220:323-325.